The New England journal of medicine
-
Letter Randomized Controlled Trial
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
-
Randomized Controlled Trial Multicenter Study
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. ⋯ In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
-
Comment Letter
Ruxolitinib for Chronic Graft-versus-Host Disease. Reply.